



Danish Patent & Trademark office awards another patent to FOM Technologies' 51% owned subsidiary.

6.7.2022 07:30:00 CEST | FOM Technologies | Investor News

Investor news no. 19 – 2022 | Copenhagen, the 6th of July 2022

FOM Technologies' 51% owned subsidiary MLMC Therapeutics ApS has been granted another process patent using Slot-die coating, thereby paving the future way for FOM Technologies to provide equipment for development of new ground-breaking manufacturing of medicine.

The 51% owned subsidiary MLMC Therapeutics ApS has been granted yet another patent method for manufacturing of multi-layered microstructures, that could be used for development and optimized manufacturing of future medicine.

CEO of FOM Technologies Michael Stadi explains: *"As FOM Technologies' core business is not to develop medicine, we have chosen to establish a separate subsidiary for this purpose, while bringing external senior pharmaceutical experts into the subsidiary's ownership and board. A separate legal entity (MLMC Therapeutics ApS) gives us an opportunity to focus on Slot-die coating in the parent company (FOM Technologies A/S), while we have created a platform for future development of medical manufacturing methods in the subsidiary."*

-----//-----

KONTAKT INFORMATION | CONTACT INFORMATION:

Selskab | Company:

FOM Technologies A/S
CEO Michael Stadi
Tlf: +45 20 66 60 44
E-mail: ms@fomtechnologies.com
www.fomtechnologies.com

Certified Advisor | Certified Advisor:

Norden CEF A/S
John Norden
Tlf: +45 20 72 02 00
E-mail: jn@nordencef.dk
www.nordencef.dk

Kommunikation | Communication

Gullev & Co. ApS
Boris Gullev
Tlf: +45 31 39 79 99
E-mail: borisgullev@gmail.com
www.gullev.co

-----//-----

- Michael Stadi, CEO, +45 20 66 60 44, ms@fomtechnologies.com

Attachments

- [Download announcement as PDF.pdf](#)